Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...

US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).

New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating ...

Oppenheimer reiterates a Perform rating on Cartesian Therapeutics (RNAC) without a price target following the company’s Q4 report. The ...

Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Antibody-drug conjugate (ADC) specialist Sutro Biopharma has shelved its lead drug for ovarian cancer and turned its ...

According to the latest study from BCC Research, "Technical Textiles: Global Markets," is expected to grow from $213.8 billion in 2024 to $284.0 billion by the end of 2029, at a compound annual growth ...